Novartis manifests future immunology pipelines
Novartis is making strong immunology portfolio by investing in immunological diseases such as spanning hidradenitis suppurativa (HS), chronic spontaneous urticaria (CSU), Sjogrens syndrome, axial spondyloarthritis, and psoriasis.
Novartis will showcase data from its leading immunology portfolio and emerging pipeline at the upcoming 31st European Academy of Dermatology and Venereology (EADV) Congress and the 15th International Symposium on September 7–10, 2022.